Glottic Carcinoma Clinical Trial
Official title:
A Phase II Study of Glottic Larynx Stereotactic Ablative Radiotherapy (LT-SABR) for Early-Stage Glottic Larynx Cancer
The goal of treatment with radiation therapy is to deliver as high of a dose as possible to the target (tumor), while minimizing the dose to the normal tissues where late-side effects can drastically affect patient quality of life.
Radiation will be delivered twice per week for 5 fractions (42.5 Gy cohort, low-risk) or daily for 16 fractions (58.08 Gy cohort, moderate-risk). Low-risk is defined by: - Planning target volume (PTV) less than 10 cc, AND - No reported smoking within 1 month from registration Moderate-risk is defined by: - Planning target volume (PTV) greater than or equal to 10 cc, OR - Smoking within 1 month from registration (no more than 1 pack per day) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04447456 -
Comparison of Voice Results at 5 Years of Treatment of Glottic Squamous Cell Carcinoma T1 by Surgery Versus Radiotherapy
|
||
| Recruiting |
NCT05688488 -
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05679856 -
Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer
|
N/A | |
| Recruiting |
NCT04908696 -
Clinical Treatments in Specialized Disease of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
|